EP0948612A2 - Toxicite de la beta-amyloide - Google Patents

Toxicite de la beta-amyloide

Info

Publication number
EP0948612A2
EP0948612A2 EP97952623A EP97952623A EP0948612A2 EP 0948612 A2 EP0948612 A2 EP 0948612A2 EP 97952623 A EP97952623 A EP 97952623A EP 97952623 A EP97952623 A EP 97952623A EP 0948612 A2 EP0948612 A2 EP 0948612A2
Authority
EP
European Patent Office
Prior art keywords
animal
gene
transgenic
transgene
transparent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97952623A
Other languages
German (de)
English (en)
Inventor
Christopher Link
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Technology Corp
Original Assignee
University of Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Technology Corp filed Critical University of Technology Corp
Publication of EP0948612A2 publication Critical patent/EP0948612A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/033—Rearing or breeding invertebrates; New breeds of invertebrates
    • A01K67/0333—Genetically modified invertebrates, e.g. transgenic, polyploid
    • A01K67/0335—Genetically modified worms
    • A01K67/0336—Genetically modified Nematodes, e.g. Caenorhabditis elegans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/70—Invertebrates
    • A01K2227/703—Worms, e.g. Caenorhabdities elegans
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0337—Animal models for infectious diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0393—Animal model comprising a reporter system for screening tests
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Definitions

  • the present invention is in the field of medicine and molecular biology.
  • the invention provides transgenic non-human animals in which expression of a reporter gene is induced by a toxic transgene.
  • the invention also provides methods and compositions for in vivo visualization of the toxicity associated with toxic proteins.
  • the present invention provides methods and compositions for the production and use of transgenic non-human animals for screening candidate drugs to assess and treat toxicity.
  • Alzheimer's disease is associated with the majority of dementia cases in the United States, with an estimated 2 million people afflicted with the disease, and a mortality rate of approximately 100,000 people per year (See, R.W.P. Cutler, "Degenerative and Hereditary
  • Alzheimer's disease Patients suffering from Alzheimer's disease typically suffer progressive memory deficit, progressive decline in cognitive functions, anxiety, depression, visuospatial and speech deficits, delusions, personality changes, motor skill deterioration, loss of verbal ability, and incontinence. Eventually, patients are completely incapacitated and disoriented, requiring total care. The course of Alzheimer's disease ranges from less than three years to over 20 years before death occurs. However, in typical cases, it progresses at a fairly constant rate, with an average duration of 6 to 10 years. Alzheimer's disease is not the only cause of dementia. Indeed, there are over fifty recognized causes of dementia. As some causes of dementia are amenable to treatment, differential diagnosis of patients suffering dementia is particularly important. Because at least 20% of clinically diagnosed patients were found at autopsy to have had conditions other than Alzheimer's disease, the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and Alzheimer's Disease and Related Disorders
  • NINCDS National Institute of Neurological and Communicative Disorders and Stroke
  • Alzheimer's disease was refined the clinical diagnostic criteria for Alzheimer's disease (See, M.A. Jenike, "Psychiatry,” in Medicine, Scientific American, New York, [1991], pages 13 (V):l-5). Based on these criteria, the diagnosis of Alzheimer's disease may be "definite” (i.e., requiring examination of brain tissue), "probable” (i.e., patients have deficits in two or more areas of cognition, insidious onset of disease, progressive worsening of memory and other cognitive functions, and normal consciousness levels), or "possible” (i.e., patents meet the criteria for probable Alzheimer's disease, but exhibit variations in the disease course or have a systemic illness that is sufficient to cause dementia, but is not considered to be the cause of the dementia).
  • definite i.e., requiring examination of brain tissue
  • probable i.e., patients have deficits in two or more areas of cognition, insidious onset of disease, progressive worsening of memory and other cognitive functions, and normal consciousness levels
  • the histopathological lesions of Alzheimer's disease include neuritic or senile plaques, neurofibrillary degeneration, and granulovacuolar neuronal degeneration.
  • the senile plaques usually contain a core of insoluble, amyloidic extracellular material (" ⁇ - amyloid) surrounded by a halo of neurofibrillary tangles and dystrophic neurons.
  • amyloidic core of senile plaques The primary protein component of the amyloidic core of senile plaques is a 4.2 kd amyloid ⁇ peptide (often referred to as "A ⁇ ").
  • a number of other proteins have also been identified as components of senile plaques, including anti-chymotrypsin and apolipoprotein E.
  • the major component of the neurofibrillary tangles is an abnormally phosphorylated microtubule-associated protein referred to as "tau.”
  • the ⁇ -amyloid protein in senile plaques is a small glycoprotein (i.e., a 39-43 amino acid protein, derived from the larger amyloid precursor protein), that has been detected in non-neural tissues (e.g., skin, subcutaneous tissue, and intestines) and blood vessels of Alzheimer's disease patients (See, Cutler, supra). Deposits of amyloid may be detected by their ability to bind specific dyes, such as Congo red or thioflavin S. Thus, it has been further hypothesized that detection of this protein may serve as a potential diagnostic aid in the assessment of patients suffering from dementia.
  • Alzheimer's disease usually arises spontaneously, although genetics play a role in development of the disease.
  • the histopathologic lesions of Alzheimer's disease have been regularly observed in the brains of older patients dying of Down's syndrome (See, Cutler, supra).
  • the ⁇ -amyloid gene resides on chromosome 21.
  • As Down's patients have an extra copy of this chromosome there is an increased expression of this chromosome in these patients.
  • increased expression of the ⁇ -amyloid gene may regulate the formation of amyloid plaques ("senile plaques") in these patients.
  • four loci were recently identified as playing a role in the genetic susceptibility of Alzheimer's disease (See, Pericak-Vance and Haines (1995) Trends Genet. 11:504).
  • Alzheimer's disease Other potential risk factors for the development of Alzheimer's disease include environmental factors (e.g., head trauma, smoking, and exposure to heavy metals), sociological factors (e.g., depression and educational level), biological factors (e.g., increasing age and hyperthyroidism), and a family history of Alzheimer's disease, Down's syndrome, or Parkinson's disease (See, Pericak-Vance and Haines, supra). Nonetheless, despite recent advances, the exact etiology and pathogenesis of Alzheimer's disease remain largely unknown.
  • environmental factors e.g., head trauma, smoking, and exposure to heavy metals
  • sociological factors e.g., depression and educational level
  • biological factors e.g., increasing age and hyperthyroidism
  • a family history of Alzheimer's disease e.g., Down's syndrome, or Parkinson's disease (See, Pericak-Vance and Haines, supra). Nonetheless, despite recent advances, the exact etiology and pathogenesis of Alzheimer's disease remain
  • cholinergic enhancers e.g., choline and lecithin
  • cholinergic precursors have been shown to be not useful, although some drugs that stimulate cholinergic transmission may be helpful in some patients.
  • physostigmine a compound that prevents the synaptic breakdown of acetylcholine.
  • the overall clinical effect of this drug has not been as dramatic as initially hoped
  • THA tetrahydroaminoacridine
  • tacrine a centrally acting anti-cholinesterase
  • Reporter genes are genes that encode proteins or other compounds that can be detected by a variety of methods, and which "report" the occurrence of successful introduction and expression of gene sequences, ⁇ -galactosidase and luciferase are examples of such reporter genes.
  • GFP green fluorescent protein
  • U.S. Patent No. 5,491 ,084 This gene can provide a method for indicating expression of a gene via fluorescent detection of GFP.
  • the drawback to using GFP in mammalian systems is as described above, that is, the need to sacrifice the mammal in order to analyze the cells and tissues of interest. This drawback is especially severe in the context of large-scale screening of potential therapeutic compounds, and U.S. Patent No. 5,491,084 does not describe a system suitable for high- throughput screening of pharmaceuticals for activity against toxic proteins expressed in cells.
  • the present invention provides methods and compositions useful for the production and use of dually transgenic animals, in particular Caenorhabditis elegans.
  • the present invention provides transparent animals that express a reporter gene inducible by a toxic transgene.
  • the toxic transgene encodes ⁇ -peptide.
  • the reporter gene is green fluorescence protein (GFP). It is contemplated that the effects or product of the reporter gene be observable (i.e., the reporter gene is expressed). For example, in embodiments in which GFP is the reporter, its presence is detected using fluorescence microscopy.
  • the animals do not need to be sacrificed in order to observe the expression of the reporter gene (i.e., the detection may be accomplished on living animals).
  • lacZ expression may be detected by exposing the tissues of the animal to the substrate for the gene (i.e., ⁇ -galactoside), and observing for the presence of blue dye in the tissues.
  • the substrate for the gene i.e., ⁇ -galactoside
  • this method requires that the animal be sacrificed in order to observe the expression of the reporter gene.
  • the genome of the transparent animal further contains a heterologous marker gene.
  • the marker gene is rol-6(su- 1006).
  • expression of the marker gene is accomplished by observing the living animals for the rolling behavior that results due to the expression of the abnormal collagen gene. In contrast, wild-type animals exhibit normal locomotion and do not exhibit this rolling behavior, as their collagen is normal.
  • the first transgene of the dually transgenic non- human animal comprises pCL25.
  • the second transgene of the dually transgenic non-human animal comprises pCL12.
  • the genome of the transparent animal further contains a heterologous marker gene.
  • the marker gene is rol-6(su-1006).
  • expression of the marker gene is accomplished by observing the living animals for the rolling behavior that results due to the expression of the abnormal collagen gene. In contrast, wild-type animals exhibit normal locomotion and do not exhibit this rolling behavior, as their collagen is normal.
  • the transparent animal is selected from the class Nematoda. Although it is not intended that the transparent animal of the present invention be limited to any specific animal, in a particularly preferred embodiment, the transparent animal is Caenorhabditis elegans. In an alternate embodiment the cells of the transparent animal display toxicity resulting from the accumulation of ⁇ -peptide within the cells. In one preferred embodiment, the genome of the transparent animal comprises SEQ ID NO: 5 and SEQ ID NO:8.
  • the present invention also provides methods for producing dually transgenic non- human animal comprising: providing: a first and second non-human animal; a first transgene comprising ⁇ -peptide; and a second transgene, comprising a reporter; introducing the first transgene into the genome of the first non-human animal to produce a first transgenic animal, and introducing the second transgene into the genome of the second non-human animal to produce a second transgenic animal; and mating the first transgenic animal with the second transgenic animal to produce a dually transgenic animal, wherein the ⁇ -peptide and the reporter are expressed.
  • the dually transgenic non-human animal is transparent.
  • the transparent animal is a nematode, while in a particularly preferred embodiment, the animal is Caenorhabditis elegans.
  • the first transgene of the dually transgenic non- human animal comprises pCL25.
  • the second transgene of the dually transgenic non-human animal comprises pCL12.
  • the genome of the transparent animal further contains a heterologous marker gene.
  • the marker gene is rol-6(su-1006).
  • expression of the marker gene is accomplished by observing the living animals for the rolling behavior that results due to the expression of the abnormal collagen gene. In contrast, wild-type animals exhibit normal locomotion and do not exhibit this rolling behavior, as their collagen is normal.
  • the present invention also comprises methods for testing compounds for anti-toxic effects, comprising: providing a dually transgenic non-human animal expressing a toxic transgene and a reporter; a composition comprising a test compound in a form suitable for administration such that the compound is bioavailable in the cells of the animal; and administering the test compound to the non-human animal.
  • the toxic transgene induces expression of the reporter gene.
  • the toxic transgene is ⁇ - peptide and the reporter gene is GFP.
  • the method further comprises the step of measuring a reduction or increase in the expression of the reporter by the dually transgenic non-human animal and thereby identifying a compound as therapeutic.
  • the compounds inactivate the ⁇ -peptide expressed by the dually transgenic animal.
  • the dually transgenic non-human animal is transparent.
  • the transparent animal is a nematode, while in a particularly preferred embodiment, the animal is Caenorhabditis elegans.
  • the first transgene of the dually transgenic non-human animal comprises pCL25.
  • the second transgene of the dually transgenic non-human animal comprises pCL12.
  • the genome of the transparent animal further contains a heterologous marker gene.
  • the marker gene is rol-6(su-1006), which produces effects described herein.
  • test compounds are tested for their ability to counter the toxic effects of transgene product. It is also contemplated that the test compounds will be tested for their ability to prevent the expression of the toxic transgene, for example, ⁇ -peptide.
  • dually transgenic animals in which the expression of, or effects of transgene toxicity, are reduced or eliminated by the test compounds are mated. The progeny of these matings are also then tested for the effects of test compounds on the expression of, or effects of toxicity. In yet another embodiment, the progeny of these matings are used in other assay systems for the identification of therapeutic compounds.
  • the dually transgenic animals of the present invention are used to identify methods suitable for the diagnostic testing of Alzheimer's disease or pathology due to other diseases.
  • the dually transgenic animals of the present invention are used to develop assays suitable for use in humans or animal models of Alzheimer's disease.
  • DESCRIPTION OF THE FIGURES Figure 1 is a diagram illustrating the construction of dual transgenic animals expressing ⁇ -amyloid peptide and an hsp/GFP reporter.
  • Figure 2 shows the DNA sequence (SEQ ID NO:5) and restriction map for pCL12.
  • Figure 3 is a graphic map of pCL12.
  • Figure 4 shows the DNA (SEQ ID NO:6), and amino acid sequence (SEQ ID NO:7) of pCL12 from nucleotide 1071 through 1253 (i.e., the ⁇ -(l-42) nucleic acid and amino acid sequence).
  • Figure 5 shows the DNA sequence (SEQ ID NO: 8) and restriction map for pGFP-
  • Figure 6 is a graphic map of pGFP-TT.
  • Figure 7 shows the DNA sequence (SEQ ID NO:9) and restriction map for pCL25.
  • Figure 8 is a graphic map of pCL25.
  • Figure 9 shows the DNA sequence (SEQ ID NO: 10) of ro/-6.
  • Figure 10 shows the amino acid sequence (SEQ ID NO:l 1) of ro/-6.
  • the present invention provides methods and compositions useful for the production and use of transgenic animals.
  • the methods and transgenic animals of the invention also provide an efficient and effective system for screening drug effective in ameloriating the effects of toxic gene products.
  • the animal used is transparent for at least part of its life cycle, for example, oocytes (Xenopus or others); larvae; pupae, fish (zebrafish or others); and nematodes, such as C. elegans.
  • C. elegans is particularly preferred because it is transparent throughout its life and has been extensively studied as a model to determine developmentally regulated gene expression, as well as pattern formation. The visibility of all of the animals' cells throughout their life cycles, has led to the complete determination of the cell lineages, and a detailed description of the morphogenic changes that occur during C. elegans development. Rapid methods for introduction of cloned DNA into the C. elegans germ line has provided means to study molecular function and expression in vivo, as the effects of the gene expression are usually readily visible in the transparent worms.
  • the methods and compositions of the present invention make use of reporter genes to monitor gene activity. Visible and quantifiable reporter genes are known and described in the art. Successfully used reporter molecules in gene fusion vectors in studies with C. elegans include the E. coli lac coding region (See e.g., A. Fire et al, (1990) Gene 93: 189- 198), and the Aequora victoria gfp coding region (See e.g., M. Chalfie et al, (1994) Science 263:802-805; D.C. Prasher et al, (1992) Gene 111:229-233; and Genbank Accession #M62654), which produces an intrinsically fluorescent protein.
  • E. coli lac coding region See e.g., A. Fire et al, (1990) Gene 93: 189- 198
  • the Aequora victoria gfp coding region See e.g., M. Chalfie e
  • transgene fusion constructs were developed as an alternative to the lacL markers, but have been available for a much shorter time (See e.g., Chalfie et al, (1994), supra; U.S.
  • Patent No. 5,491,084 Initial reports indicate that the fluorescence pattern appears to be more restricted than that exhibited by equivalent lacL fusion. In addition, there are still problems associated with the germline expression of the transgenes and ectopic expression. Indeed, in some cases, the problems with ectopic expression have been exacerbated by these "improvements.”
  • the present invention overcomes many of these problems described in the art.
  • the tranparent animals and dually transgenic animals described herein provide easily visible, stably expressed systems in which the toxic transgene and reporter gene are expressed similarly to endogenous chromosomal gene expression. These animals provide an excellent system for screening compounds having effects on the toxic transgene.
  • the present invention therefore, provides model systems for the study of human diseases and methods of identifying therapeutic compounds using these animal systems.
  • the reporter genes are operably linked to an inducible promoter.
  • the promoter is induced by the toxic transgene, for example by the gene product of the toxic transgene. It is also contemplated that the toxic transgene can act to induce the promoter indirectly, for example by disrupting other cellular proteins or functions.
  • Suitable inducible promoters are available and can be readily determined by those skilled in the art. Non-limiting examples of promoters which are induced by "stresses" include the metallothionein gene promoter (mtl-l or mtl-2; e.g., Genbank Accession #M92910, #M11794, #X00504, and #X00953), and the C.
  • elegans amyloid precursor protein (APP) homolog apl-l gene promoter See e.g., Daigle and Li, Proc. Natl. Acad., Sci., 90:12045-12049 [1993]).
  • Other potential promoters include those from other inducible heat-shock genes; at least one of the known C. elegans hsplO genes is strongly heat-inducible. It is also contemplated that promoters from genes known to be up- regulated under stress conditions in other systems (e.g., superoxide dismutase, catalase, glutathione reductase, etc.) may also be useful.
  • a strong muscle-specific promoter was used to express a potentially secretable form of the ⁇ -peptide, so as to generate significant extracellular levels of ⁇ -peptide. This was accomplished in order to mimic the situation that may exist in the human brain, and allow observations of cell- external neurotoxicity. The present inventor has also demonstrated that the promoter must be chosen so that enough ⁇ -peptide is produced to cause physiological effects, but not so much to kill the animals.
  • the wrac-54/ ⁇ -(l-42) minigene was constructed with a modified signal sequence that has been previously shown to allow secretion of a her-l protein product that is ectopically expressed in muscle cells (M.D. Perry et al, (1993) Genes Dev., 7:216-228).
  • the development of C. elegans transgenic for expression of ⁇ -amyloid was previously described by the inventor (Link, (1995) Proc. Natl Acad. Sci., 92:9368-9572).
  • ⁇ -peptide expression will be directed to other tissues, through utilization of appropriate promoters.
  • animals expressing ⁇ -peptide in the intestine may be particularly useful to analyze compounds such as drugs for their effect on ⁇ -peptide, as these cells readily take up exogenous compounds administered orally.
  • the transgene element of the present invention can be any sequence which is able to induce the promoter operably linked to the reporter gene.
  • the transgene is "toxic" in the sense that it disrupts cellular function in some way.
  • the transgene encodes a protein that is toxic to the host cells and/or organism in that it causes deleterious effects to the host, for instance interfering with the hosts ability to survive and/or grow.
  • the toxic transgenes encode proteins that disrupt cellular function directly
  • the toxic transgene comprises a gene encoding for an amyloidic protein, for example beta amyloid peptide, prion protein variants, transthyretin variants, gelsolin variants, cystatin variants, lysozyme variants and the like.
  • the transgene encodes a protein containing polyglutamine resulting from triplet-repeat expansion such as huntingtin (a protein that has been implicated in Huntington's Chorea), ataxin-1 or ataxin-2.
  • a protein containing polyglutamine resulting from triplet-repeat expansion such as huntingtin (a protein that has been implicated in Huntington's Chorea), ataxin-1 or ataxin-2.
  • proteins associated with inherent amyelotopic lateral sclerosis (ALS) for example, superoxide dismutase 1 variants and over-expressed neurofilament protein, can be used.
  • ALS amyelotopic lateral sclerosis
  • the transgene can encode for an entire toxic protein or, alternatively, a functional (i.e. toxic) fragment.
  • the present invention includes a dually transgenic non-human animal.
  • the development of these dually transgenic animals involves the production of two C. elegans lines with a single transgene in each line, designated as CL2005 and CL2070.
  • C. elegans was chosen due to the observation that the toxic effect of ⁇ -amyloid has been reported to occur in these animals, in addition to humans.
  • Line CL2005 exhibited muscle-specific expression of human ⁇ peptide
  • line CL2070 exhibited stress-inducible expression of GFP.
  • GFP was incorporated into the present invention as it provides a marker (i.e., "reporter") that is readily visible in living worms.
  • dually transgenic animals both express ⁇ -peptide in their muscle cells and under appropriate conditions for observation (i.e., fluorescence microscopy), exhibit green fluorescence in these cells.
  • the present invention provides an easily detectable method for the specific expression of ⁇ -peptide in dually transgenic animals. This ease of detection provides great advantages for the development of methods to analyze the effects of ⁇ -amyloid in vivo.
  • the dually transgenic animals are not killed in order to detect the presence of ⁇ -amyloid, as would be required if other reporters (e.g., lacL or luciferase) were used, the animals may be useful for screening compounds for their effects on ⁇ -amyloid in an in vivo situation.
  • the use of an reporter which is detectable in vivo provides significant advantages over currently available methods.
  • the present invention also includes methods of screening compounds for their ability to prevent or inhibit toxicity due to the toxic transgene.
  • the methods and animals described above can be used to identify potential therapies.
  • transgenic worms e.g., green fluorescing worms with muscle-specific ⁇ -peptide expression
  • the animals would no longer glow green.
  • the present invention provides a fast and efficient screening system, for example by using commercially available equipment for assaying multiple compounds at once.
  • transgenic animals of the present invention expressing a detectable reporter gene triggered by a toxic transgene provide animal models for human diseases.
  • a reporter gene such as GFP
  • GFP a reporter gene induced by expression of ⁇ -peptide
  • the present invention be limited to animals expressing ⁇ -peptide in conjunction with GFP.
  • expression of other proteins associated with dementia and/or Alzheimer's or other diseases would also find use in conjunction with GFP in C. elegans as well.
  • proteins including mutated versions of proteins
  • proteins such as the presenilins associated with Alzheimer's disease (See e.g., J. Marx (1996) Science 274:1838-1840) will be used in conjunction with GFP and full-length APP in dually transgenic C. elegans.
  • Other toxic proteins which provide animal models for other human diseases are described herein.
  • transgenic animals also provide a means to screen compounds for their ability to decrease or eliminate the toxicity.
  • compounds suitable for testing using the transgenic animals of the present invention include, but are not limited to, Congo Red, tumor necrosis factor (TNF), estrogen, tacrine (9-amino-l, 2,3, 4-tetrahydroacri dine), dihydroepiandrosterone (DHEA), compounds that inhibit ApoE4, and others, commercially available from suppliers such as Sigma.
  • Compounds to be tested for antitoxic activity are administered to the same number of dually transgenic animals (e.g., generated using the methods described in the Examples, below) from the control group and the treatment group, and the presence or absence of reporter gene used as a measure of efficacy.
  • the compounds being tested can be administered using any suitable route (e.g., oral, parenteral, controlled-release transdermal methods, and implants, etc.).
  • the compounds to be tested are suspended in the growth media provided to the worms.
  • the route of administration will depend on the stability of the compound, the susceptibility of the compound to "first pass" metabolism, the concentration needed to achieve a therapeutic effect, and the like.
  • a compound that appears promising i.e., which increases the number of worms which display reduced ⁇ -peptide toxicity
  • Another screening method involves the crossing of the transgenic worms of the present invention with other transgenic worms.
  • the animals are observed after treatment, in the presence and absence of the test compound(s), with the effects on the toxic transgene being gauged either by crude survival or the presence/absence of the reporter gene.
  • the methods of the present invention be modified so as to provide means to analyze disease-related proteins believed to have dominant toxic effects, by substituting appropriate sequences for the ⁇ -peptide sequences used as described in the Examples.
  • proteins such as transthyretin (known to be associated with familial amyloid polyneuropathy; See e.g., Christmason et al, (1991) FEBS 281:177-180; Genbank Accession #D00096), and variant superoxide dismutase (known to be associated with familial amyotrophic lateral sclerosis [Lou Gehrig's disease]), prion proteins, A4 amyloid protein (See e.g., Ponte et al, (1988) Nature 331:525-527; Salbaum et al, U.S. Patent No.
  • APP See e.g., Kitaguchi et al, (1988) Nature 331:530-532; Sata et al, EP Appln. 94117512.7; Scott et al, WO 9412627; Wadsworth et al, WO 9314200; Gearhart et al, WO 9423049; and Neve et al, WO
  • amyloidic proteins e.g., variant lysozymes and amylin peptide
  • other proteins associated with neuronal degeneration See e.g., U.S. Patent No. 5,196,333
  • animals transgenic for dual proteins e.g., ⁇ -peptide in combination with another protein, such as transthyretin
  • the present invention provides the means to analyze the effects of numerous genes and proteins in vivo.
  • transgenic animals of the present invention provide distinct advantages over other transgenic animals currently used to analyze diseases such as Alzheimer's disease. Due to the short gestation period of C. elegans, transgenic animals can be produced much more rapidly than when mammals, such as mice are used. For example, transgenic mice overexpressing a 695 amino acid isoform of ⁇ -amyloid precursor did not show learning and memory impairment until they were 9-10 months of age (Hsiao et al, Science 274:99-102 [1996]). In contrast, the transgenic animals of the present invention express ⁇ -peptide and may be manipulated at a very early age, even in embryonic stages.
  • transgenic animals are easy to select based on the presence of the green fluorescence, invasive procedures such as surgery, necessary to analyze the effects of the toxic transgene in other animals (e.g., mice) are avoided.
  • the present invention provides methods and compositions useful as animal models for disease, as well as providing methods and compositions for disease therapy and prevention.
  • the animal testing may be supplemented and confirmed by testing on human subjects.
  • the transgenic animals of the present invention allow the testing of a large number of compounds, both various methods, including those known in the art.
  • non-human animal includes vertebrates such as rodents, arthropods, insects (e.g., Diptera), fish (e.g., zebrafish), non-human primates, ovines, bovines, ruminants, lagomorphs, porcines, caprines, equines, canines, felines, aves, etc.
  • the non- human animal can be used at any stage in its development, for example oocyte, fetal, larval, pupal stages or the like.
  • Preferred non-human animals are those that are transparent, such as certain nematodes, oocytes, larvae and fish.
  • the term "transparent" is used in references to animals through which light will be transmitted. However, it is not intended that the amount of light transmittance be limited to any particular amount.
  • an animal is transparent so long as at least some light may be transmited through its body.
  • Non-limiting examples of transparent animals are larval stages of some animals (e.g., flies) and oocytes (e.g., Xenopus oocytes).
  • Particularly preferred non-human animals are selected from the nematodes (i.e., any animal in the Class Nematoda), most preferably Caenorhabditis elegans.
  • other transparent animals such as zebrafish will be useful in the present invention.
  • transgenic zebrafish have been produced (See e.g., Lin et al, PCT Publ. WO9603034; incorporated herein by reference).
  • the "non-human animals having a genetically engineered genotype” of the invention are preferably produced by experimental manipulation of the genome of the germline of the non-human animal.
  • These genetically engineered non-human animals may be produced by several methods including the introduction of a "transgene” comprising nucleic acid (usually DNA) into an embryonal target cell or integration into a chromosome of the somatic and/or germ line cells of a non-human animal by way of human intervention, such as by the methods described herein.
  • transgenic non-human animals The process by which a DNA molecule becomes stably incorporated into another genome is referred to as "stable integration."
  • stable integration Non-human animals which contain a transgene are referred to as "transgenic non-human animals”.
  • transgenic animal is an animal whose genome has been altered by the introduction of one or more transgenes.
  • transgene refers to a foreign gene that is placed into an organism by introducing the foreign gene into gonadal cells, embryonic cells, newly fertilized eggs, or early embryos.
  • foreign gene refers to any nucleic acid (e.g., gene sequence) which is introduced into the genome of an animal by experimental manipulations and may include gene sequences found in that animal so long as the introduced gene contains some modification relative to the naturally-occurring gene.
  • a preferred foreign gene is the ⁇ -amyloid gene (e.g., ⁇ -peptide), or fragments thereof.
  • a "toxic transgene” refers to a foreign gene which disrupts cellular function in some way. For example, the toxic transgene may produce a gene product (i.e., protein) which is toxic to the cell or organism. Alternatively, the transgene may disrupt other cellular proteins, or act as a DNA binding site without producing a protein.
  • toxicity refers to the production of toxic effects by any compound or substance.
  • ⁇ -peptide toxicity may arise due to the accumulation of ⁇ - peptide molecules.
  • toxicity associated with ⁇ -peptide may be manifested as negative effects on muscle cells of dually transgenic animals.
  • promoter element refers to a DNA sequence that is located at the 5' end of (i.e., precedes) a gene in a DNA polymer and provides a site for initiation of the transcription of the gene into mRNA.
  • inducible promoter is a promoter that is triggered by certain signals within the cell, for instance binding of a transcription factor, stress, heat or the like.
  • reporter gene refers to genes that encode proteins or other compounds that can be detected by a variety of methods. These genes "report” the occurrence of successful introduction and expression of sequences such as transgenes.
  • Non-limiting examples of reporter genes include antibiotic resistance genes, genes encoding enzymes and genes encoding other detectable proteins. Expression of the reporter gene is detected using methods known in the art.
  • the reporter gene is a GFP gene, although lacZ ⁇ -galactosidase gene, or any other reporter system may be used to detect the successful production of transgenic animals.
  • the reporter is a compound or protein which may be present or expressed within living animals. That is, it is not necessary to sacrifice the animal in order to detect the presence of the reporter.
  • the type of the reporter gene system used is not critical to the invention, and it is contemplated that any system suitable for use with the transgenic animals of the present invention will be used.
  • the terms “dual trangenic” and “dually transgenic” refer to animals or cells in which more than one transgene have been introduced.
  • the term is used in reference to cells which contain the sequences encoding ⁇ -peptide, and sequences encoding a reporter (e.g., GFP).
  • a reporter e.g., GFP
  • the number of transgenes in the dually transgenic animals of the present invention be limited to two.
  • the transgenic animals may also contain another one or more marker genes (e.g., rol-6 sequences), in addition to ⁇ -peptide and reporter sequences.
  • expression of the marker gene is accomplished by observing the living animals for the rolling behavior that results due to the expression of the abnormal collagen gene.
  • wild-type animals exhibit normal locomotion and do not exhibit this rolling behavior, as their collagen is normal.
  • the transgenic animals of the present invention are preferentially generated by introduction of the targeting vectors into gonad cells.
  • Transgenes can be efficiently introduced into the cells by DNA transfection using a variety of methods known to the art, including electroporation, calcium phosphate co-precipitation, protoplast or spheroplast fusion, lipofection, and DEAE-dextran-mediated transfection.
  • Transgenes may also be introduced into cells by retrovirus-mediated transduction or by micro-injection.
  • the transgenes are injected into gonads of C. elegans as described by Mello et al. (1991) EMBO J., 10:3959-3970.
  • transgenic animals containing an altered gene are known to the art. For example, embryonal cells at various developmental stages can be used to introduce transgenes for the production of transgenic animals. Different methods are used depending on the stage of development of the embryonal cell.
  • Means for producing labeled hybridization or PCR probes for detecting related sequences include oligolabeling, nick translation, and end-labeling or PCR amplification using a labeled nucleotide.
  • Suitable reporter molecules or labels include those radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles and the like.
  • the term may also be used in reference to proteins.
  • a variety of protocols which employ polyclonal or monoclonal antibodies specific for the ⁇ -peptide protein product are known in the art (See, the Examples). These antibodies can be used as markers for the expression of proteins. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS).
  • gene refers to a DNA sequence that comprises coding sequences necessary for the production of a polypeptide or precursor. In some instances, a gene can also include control sequences.
  • the polypeptide can be encoded by a full length coding sequence or by any portion of the coding sequence so long as the desired enzymatic activity is retained.
  • gene of interest refers to any gene, the manipulation of which may be deemed desirable for any reason, by one of ordinary skill in the art.
  • wild-type refers to a gene or gene product which has the characteristics of that gene or gene product when isolated from a naturally occurring source.
  • a wild-type gene is that which is most frequently observed in a population and is thus arbitrarily designed the "normal” or “wild-type” form of the gene.
  • modified or mutant refers to a gene or gene product which displays modifications in sequence and or functional properties (i.e., altered characteristics) when compared to the wild-type gene or gene product. It is noted that naturally-occurring mutants can be isolated; these are identified by the fact that they have altered characteristics when compared to the wild-type gene or gene product.
  • targeting vector or “targeting construct” refer to oligonucleotide sequences comprising a gene of interest flanked on either side by regulatory sequences.
  • the targeting vector is capable of homologous recombination such that the gene of interest is integrated by recombination.
  • vector and “vehicle” are used interchangeably in reference to nucleic acid molecules that transfer DNA segment(s) from one cell to another.
  • expression vector or “expression cassette” as used herein, refers to a recombinant DNA molecule containing a desired coding sequence and appropriate nucleic acid sequences necessary for the expression of the operably linked coding sequence in a particular host organism.
  • Nucleic acid sequences necessary for expression in prokaryotes usually include a promoter, an operator (optional), and a ribosome binding site, often along with other sequences.
  • Eukaryotic cells are known to utilize promoters, enhancers, and termination and polyadenylation signals.
  • operable combination refers to the linkage of nucleic acid sequences in such a manner that a nucleic acid molecule capable of directing the transcription of a given gene and/or the synthesis of a desired protein molecule is produced.
  • the term also refers to the linkage of amino acid sequences in such a manner so that a functional protein is produced.
  • tissue-type specific refers to a promoter that is capable of selectively directing expression of a gene in a specific tissue.
  • tissue-specific promoter in the method of the present invention does not require absolute specificity. In general, the requisite specificity is found where a plurality (or, more preferably, a majority) of cells in one tissue type express a gene of interest, while virtually all (e.g., greater than 80%, and preferably greater than 90%, and more preferably greater than 95%), of the cells in other tissue types do not.
  • the strong muscle promoter unc54 was used (See, Example 1).
  • portion when in reference to a gene refers to fragments of that gene.
  • the fragments may range in size from a few nucleotides to the entire gene sequence minus one nucleotide.
  • an oligonucleotide comprising at least a portion of a gene may comprise fragments of the gene or the entire gene.
  • substantially purified refers to molecules, either nucleic or amino acid sequences, that are removed from their natural environment, isolated or separated, and are at least 60% free, preferably 75% free, and most preferably 90% free from other components with which they are naturally associated.
  • An "isolated polynucleotide” is therefore a substantially purified polynucleotide.
  • PCR polymerase chain reaction
  • the mixture is denatured and the primers then annealed to their complementary sequences within the target molecule.
  • the primers are extended with a polymerase so as to form a new pair of complementary strands.
  • the steps of denaturation, primer annealing and polymerase extension can be repeated many times (i.e. , denaturation, annealing and extension constitute one "cycle”; there can be numerous "cycles") to obtain a high concentration of an amplified segment of the desired target sequence.
  • the length of the amplified segment of the desired target sequence is determined by the relative positions of the primers with respect to each other, and therefore, this length is a controllable parameter.
  • PCR polymerase chain reaction
  • PCR it is possible to amplify a single copy of a specific target sequence in genomic DNA to a level detectable by several different methodologies (e.g., hybridization with a labeled probe; incorporation of biotinylated primers followed by avidin-enzyme conjugate detection; and/or incorporation of 32 P-labeled deoxynucleotide triphosphates, such as dCTP or dATP, into the amplified segment).
  • any oligonucleotide sequence can be amplified with the appropriate set of primer molecules.
  • the amplified segments created by the PCR process itself are, themselves, efficient templates for subsequent PCR amplifications.
  • Amplified target sequences may be used to obtain segments of DNA (e.g., genes) for the construction of targeting vectors, transgenes, etc.
  • PCR product and “amplification product” refer to the resultant mixture of compounds after two or more cycles of the PCR steps of denaturation, annealing and extension are complete. These terms encompass the case where there has been amplification of one or more segments of one or more target sequences.
  • the term "Central Nervous System” refers to the "spinal cord” and the "brain.”
  • the spinal cord comprises white areas and grey areas.
  • the grey area contains nerve cell bodies, whereas the white area is essentially comprised of myelinated nerves.
  • the brain which is also known as the encephalon, is that portion of the cerebrospinal axis which is contained in the cavity of the cranium.
  • the brain comprises the two cerebral hemispheres, the inter- brain, the mid-brain, the pons Varolli and cerebellum, and the medulla oblongata.
  • the two hemispheres together with the parts derived from the thalamencephalon form the forebrain.
  • the two cerebral hemispheres are separated by the longitudinal fissure and also comprise the bylvian fissure, the fissure of Rolando, and the parieto-occipital fissure.
  • the lobes on the external surface of the brain comprise the frontal lobe, the parietal lobe, the occipital lobe, and the temporal lobe.
  • Placed along the middle line of the brain are, among others, the rostrum and peduncles of corpus callosum, lamina cinera, optic commissure and the pituitary body.
  • On each side of the middle line lies the frontal lobe, olfactory lobe and the hemisphere of cerebellum.
  • nerve cells are composed of the nerve cell body (perikaryon), one or more dendrites, and an axon. Neurons can be classified according to the number of processes originating from the cell body. Thus, unipolar neurons have a single process, bipolar neurons have one axon and one dendrite, while multipolar neurons (which are the most common) comprise more than two processes.
  • nerve comprises cholinergic neurons and sensory neurons.
  • cholinergic neuron means a neuron in the Central Nervous System (CNS) and in the Peripheral Nervous System (PNS) whose neurotransmitter is acetylcholine.
  • PNS Peripheral Nervous System
  • sensor neuron includes a neuron which is responsive to environmental cues (e.g., temperature and movement) from, for example, the skin, muscle and joints of a mammal.
  • neural refers to two or more neurons arranged in linear sequence such that the axon of one neuron establishes a structural and functional link with the dendrite of a second neuron to form a "synapse.”
  • a compound refers to any chemical entity, pharmaceutical, drug, and the like that can be used to treat or prevent a disease, illness, sickness, or disorder of bodily function.
  • Compounds comprise both known and potential therapeutic compounds.
  • a compound can be determined to be therapeutic by testing using the testing methods of the present invention (i.e., a "test compound”).
  • a "known therapeutic compound” refers to a therapeutic compound that has been shown (e.g., through animal trials or prior experience with administration to humans) to be effective in such treatment or prevention. In other words, a known therapeutic compound is not limited to a compound efficacious in the treatment or prevention of neural related disorders.
  • a compound is said to be "in a form suitable for administration such that the compound is bioavailable in the blood of the animal" when the compound may be administered to an animal by any desired route (e.g., oral, intravenous, subcutaneous, intramuscular, etc.) and the compound or its active metabolites appears in the blood of the animal in an active form.
  • Administration of a compound to a pregnant animal may result in delivery of bioavailable compound to the embryonic progeny of the animal.
  • wild-type ⁇ -amyloid or " ⁇ -peptide” gene and gene product refers to the nucleotide and amino acid sequences provided in SEQ ID NOS:6 and 7, respectively.
  • SEQ ID NOS:6 and 7 certain modifications of SEQ ID NOS:6 and 7 can be made which will not interfere with the production of a polypeptide having an activity indistinguishable from that of the wild-type ⁇ -amyloid; the present invention specifically contemplates these variant forms of ⁇ -amyloid.
  • a "variant" of the ⁇ -peptide is defined as an amino acid sequence that differs by one or more amino acids.
  • the variant may have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties (e.g., replacement of leucine with isoleucine). More rarely, a variant may have "nonconservative" changes, e.g., replacement of a glycine with a tryptophan. Similar minor variations may also include amino acid deletions or insertions (i.e., additions), or both. Guidance in determining which and how many amino acid residues may be substituted, inserted or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art, for example, DNAStar software.
  • an oligonucleotide sequence comprising at least a portion of a human ⁇ - amyloid gene refers to a polynucleotide sequence (i.e., a nucleic acid sequence) containing a nucleotide sequence derived from a human ⁇ -amyloid gene. This sequence may encode a portion or all of the ⁇ -amyloid protein; alternatively, this sequence may contain non-coding regions derived from the ⁇ -amyloid gene or a combination of coding and non-coding regions.
  • the oligonucleotide may be RNA or DNA and may be of genomic or synthetic origin.
  • portion when in reference to a gene refers to fragments of that gene.
  • the fragments may range in size from 10 nucleotides to the entire gene sequence minus one nucleotide.
  • an oligonucleotide comprising at least a portion of a gene may comprise fragments of the gene or the entire gene.
  • heterologous marker gene an animal whose genome contains a marker gene not naturally found in the animal's genome.
  • the heterologous marker gene is a mutant collagen gene, such as the rol-6 (su- 1006) gene.
  • rol-6 ser- 1006 gene.
  • other marker genes will be used with success in the present invention, including other mutant collagen genes, as well as other marker genes commonly known to those in the art.
  • diagnostic assay refers to methods for the diagnosis of disease, illness, and/or pathology. It is intended that the term encompass any methods for diagnosis, including, but not limited to assays based on immunoreactivity (e.g., radioimmunoassays, fluorescence immunoassays, enzyme immunoassays), histochemistry, dye retention or binding (e.g., fixing of dyes such as Congo Red), nucleic acid based diagnostic methods (e.g., identification of nucleic acid sequences associated with disease or pathology), etc.
  • immunoreactivity e.g., radioimmunoassays, fluorescence immunoassays, enzyme immunoassays
  • histochemistry e.g., fixing of dyes such as Congo Red
  • dye retention or binding e.g., fixing of dyes such as Congo Red
  • nucleic acid based diagnostic methods e.g., identification of nucleic acid sequences associated with disease or pathology
  • the amplification product was cleaved with Kpnl and Sad, and inserted between the unique Kpnl and Sac I sites of pCL2, to generate "pCL3.”
  • the signal peptide/ ⁇ -(l-42) minigene fragment was removed from this plasmid by digestion with Nhel and Sacl, and inserted between the unique Nhel and Sad sites of pPD30.38, to produce "pCL12."
  • the sequence of the ⁇ -(l-42) minigene was confirmed by dideoxy DNA sequencing of the coding strand only, by techniques known in the art.
  • the sequence of pCL12 (SEQ ID NO:5), is shown in Figure 2.
  • a graphic map of pCL12 is provided at Figure 3.
  • Figure 4 shows the DNA and amino acid sequences (SEQ ID NOS: 6 and 7, respectively) of pCL12 from nucleotide 1071 through 1253 (i.e., the ⁇ (l-42) nucleic acid and amino acid sequences) present in the construct.
  • the expression vector (“pCL25”) containing the hsp/GFP reporter which drives the expression of the GFP-TT gene was constructed.
  • This vector was used in subsequent experiments (See, Example 3) to produce transgenic C. elegans was constructed.
  • GFP-TT is a modified form of GFP that contains Ser65Thr and Ilel67Thr (the numbering is relative to the sequence of the wild-type GFP). The substitutions present in GFP-TT produce a protein which results in the production of a much brighter fluorescence than the wild-type GFP.
  • pCL25 was constructed as described below.
  • a 431 bp Hindlll-BamYll fragment containing the hspl6-2 promoter was excised from the plasmid "pPD49.78,” by digestion with BamUl and HmdIII.
  • This 431 bp Hindl ⁇ l-BamHl fragment was inserted between the HmdIII (nucleotide #1) and Bam ⁇ l (nucleotide #31) sites of the GFP-TT gene in the plasmid "pGFP-TT,” (available from Yishi Jin, at the University of California, Santa
  • the pGFP-TT plasmid contains the coding regions for GFP-TT inserted into a Tu61 backbone.
  • the DNA sequence of pGFP-TT (SEQ ID NO: 8) is shown in Figure 5.
  • a schematic map of pGFP-TT is shown in Figure 6, in which unique restriction sites are shown.
  • the pGFP-TT plasmid was digested with HmdIII and Bam ⁇ l, and the 431 bp fragment containing the hspl6-2 promoter was inserted, in order to generate the stress-inducible expression vector "pCL25.”
  • the DNA sequence of pCL25 (SEQ ID NO:9) and restriction map are shown in Figure 7.
  • Figure 8 provides a schematic map of pCL25 in which unique restriction sites are shown.
  • the transgenic parent animals were produced, with one line expressing the ⁇ (l-42) minigene (designated as "CL2005") and the other line expressing the hsp/GFP reporter (designated as "CL2070").
  • the transgenes were introduced into C. elegans by gonad microinjection as known in the art and described by Mello et al. (Mello et EMBO J., 10:3959-3970 [1991]).
  • Marker plasmid pRF4 containing the gene (ro/-6 " [sul006]) (SEQ ID NO:9)(pRF4 carries a 4 kb EcoRI fragment of C. elegans genomic DNA containing the r /-6[sul006] collagen gene in the Bluescribe vector
  • the (rol-6[sul006J) gene (SEQ ID NO:9), contained within the pRF4 plasmid is a mutated C. elegans collagen gene, the expression of which produces the dominant, distinctive
  • Transmitting lines were established and maintained by selection for the Roller marker phenotype.
  • Transgenic animals produced in this manner maintain the injected DNA as an extrachromosomal, multicopy array of variable mitotic and meiotic stability.
  • Transgenic (i.e., as indicated by the Roller phenotype) animals produce both transgenic (i.e., Roller) and non-transgenic (i.e., non-Roller) progeny. These non- transgenic progeny were found to serve as good internal controls for phenotypic and immunohistochemical comparisons.
  • the expression of GFP in the dual transgenic animals can be detected in less than 24 hours after the upshift of animals from 16 to 25.5°C, at all stages of development, from late embryonic to adult. Expression of GFP resulted in the production of green fluorescence in muscle cells; intense tissue-specific expression of GFP was observed.
  • the fluorescence can be observed using compound or dissecting epifluoroescence microscopy (i.e., with standard fluorescein excitation and emission filters). It is also contemplated that the fluorescence is observable by use of fluorimeters and cell sorters.
  • 5 / ⁇ (l-42) minigene construct contained muscle-specific deposits of anti- ⁇ peptide immunoreactivity.
  • Non anti- ⁇ -immunoreactivity was observed in control animals (i.e,, non-transgenic, wild-type C. elegans tested concurrently).
  • C. elegans is reported to contain a homolog of the ⁇ -amyloid precursor protein gene (See, Daigle and Li, Proc. Natl. Acad. Sci., 90:2045-2049 [1993]), this sequence does not contain an apparent ⁇ - peptide domain. Thus, it would not be expected, nor did it show, cross-reactivity with the anti- ⁇ antibody used in these experiments.
  • immunoreactive deposits accumulated in the body wall of the animals.
  • Muscle-specific ⁇ peptide deposits were observed, and showed a qualitative correlation with the level of GFP expression in these muscle cells (i.e., cells that contained more ⁇ -peptide deposits were more green than cells with less ⁇ -peptide deposits).
  • Congo Red and Chrysamine G two dyes known to interact with ⁇ - amyloid and have been reported to interfere with its aggregation are tested on the dually transgenic animals.
  • Anti-oxidants e.g., vitamin E and ascorbate
  • interference with aggregation of ⁇ -peptide, or interaction with ⁇ -amyloid are observed.

Abstract

Procédés et compositions pour la visualisation des effets toxiques de transgènes in vivo. En particulier, procédés et compositions pour produire et utiliser Caenorhabditis elegans transgénique, y compris doublement transgénique, afin de visualiser les effets toxiques de l'accumulation de β-amyloïde in vivo.
EP97952623A 1997-01-03 1997-12-31 Toxicite de la beta-amyloide Withdrawn EP0948612A2 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US77864597A 1997-01-03 1997-01-03
US8022297P 1997-01-03 1997-01-03
US778645 1997-01-03
US80222P 1997-01-03
PCT/US1997/023819 WO1998028971A2 (fr) 1997-01-03 1997-12-31 Toxicite de la beta-amyloide

Publications (1)

Publication Number Publication Date
EP0948612A2 true EP0948612A2 (fr) 1999-10-13

Family

ID=26763238

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97952623A Withdrawn EP0948612A2 (fr) 1997-01-03 1997-12-31 Toxicite de la beta-amyloide

Country Status (3)

Country Link
EP (1) EP0948612A2 (fr)
AU (1) AU5619298A (fr)
WO (1) WO1998028971A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1294450B1 (it) * 1997-08-28 1999-03-25 Consiglio Nazionale Ricerche Animali transgenici per lo studio di agenti tossici chimici fisici o biologici
WO2000021362A1 (fr) * 1998-10-09 2000-04-20 The Regents Of The University Of California ANIMAUX TRANSGENIQUES PrP (PROTEINE DE PRION) VIABLES ET PROCEDES D'UTILISATION
DE19849073A1 (de) * 1998-10-24 2000-04-27 Aventis Pharma Gmbh Transgener C. elegans als Modellorganismus für Untersuchungen zur Alzheimer'schen Krankheit
WO2000036106A2 (fr) * 1998-12-17 2000-06-22 Xenogen Corporation Evaluation non-invasive d'une reponse physiologique chez un mammifere
GB9906018D0 (en) * 1999-03-16 1999-05-12 Devgen Nv Expression of DNA or proteins in C.elegans
WO2001018225A1 (fr) * 1999-09-03 2001-03-15 Xenogen Corporation Constructions de ciblage et animaux transgeniques produits avec ces constructions
US6867348B1 (en) 1999-12-16 2005-03-15 Xenogen Corporation Methods and compositions for screening for angiogenesis modulating compounds
IT1311335B1 (it) 1999-12-21 2002-03-12 Otc Optical Technologies Ct S Procedimento e dispositivo per realizzare reticoli in fibra ottica.
JP3354918B2 (ja) 2000-06-08 2002-12-09 佑子 若松 透明メダカ
CA2469135A1 (fr) * 2001-11-27 2003-06-05 Nexyte Ab Production de molecules de proteines et d'acides nucleiques eucaryotes dans c. elegans
FR2840320B1 (fr) * 2002-05-30 2007-07-20 Centre Nat Rech Scient Embryons transgeniques de xenope et leurs utilisations pour la detection de perturbateurs endocriniens, et procedes correspondants
GB0517977D0 (en) * 2005-09-02 2005-10-12 Birkeland Innovasjon As Transgenic animal model for identifying modulators of protein kinase
DE102007035238A1 (de) * 2007-07-27 2009-01-29 Christian-Albrechts-Universität Zu Kiel Biologisches Effektmonitoring mittels transgener Hydra
WO2011017319A1 (fr) 2009-08-03 2011-02-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Méthodes de traitement de troubles associés à la polymérisation d'une protéine
US8809617B2 (en) * 2009-11-05 2014-08-19 The University of Pittsburgh—Of the Commonwealth System of Higher Education Automated high-content live animal drug screening using C. elegans
US9072772B2 (en) 2009-11-05 2015-07-07 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating disorders associated with protein aggregation
CN104920307B (zh) * 2015-06-19 2018-01-26 安徽省农业科学院农业工程研究所 一种适用于单粒子微束装置的秀丽小杆线虫固定方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4240293A (en) * 1992-05-08 1993-12-13 Exemplar Corporation Anti-neoplastic in vivo drug screen
CA2088379A1 (fr) * 1993-01-29 1994-07-30 University Of British Columbia Systemes biologiques comportant des genes inductibles par le stress et proteines decelables pour la biosurveillance et la toxicologie environnementale
EP1001019A1 (fr) * 1993-10-27 2000-05-17 Athena Neurosciences, Inc. Animaux transgéniques hébergeant un gène allele APP présentant une mutation suédoise

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9828971A3 *

Also Published As

Publication number Publication date
WO1998028971A2 (fr) 1998-07-09
WO1998028971A3 (fr) 1998-10-29
AU5619298A (en) 1998-07-31

Similar Documents

Publication Publication Date Title
Edelmann et al. Neuronal abnormalities in microtubule-associated protein 1B mutant mice.
AU671093B2 (en) Transgenic animal models for alzheimer's disease
EP0948612A2 (fr) Toxicite de la beta-amyloide
Davis et al. An Alzheimer's disease-linked PS1 variant rescues the developmental abnormalities of PS1-deficient embryos
EP1005542B1 (fr) Souris TRANSGENIQUES DANS LESQUELS L'EXPRESSION DE L'APOLIPOPROTEINE E EST ALTEREE ET PROCEDES DE DOSAGE ASSOCIES
Götz et al. Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy
US20100146645A1 (en) Transgenic animal model for modelling pathological anxiety, a method for identifying compounds for treatment of diseases or disorders caused by pathological anxiety and a method for using wfs1 protein as a target for identifying effective compounds against pathological anxiety
US20080201786A1 (en) Transgenic Zebrafish Models of Alzheimer's Disease
JP2001517065A (ja) トランスジェニック動物モデルを用いてアルツハイマー病治療薬を同定する方法
JP4290329B2 (ja) 遺伝子変異動物
US20030233669A1 (en) Perlecan transgenic animals and methods of identifying compounds for the treatment of amyloidoses
US8487087B2 (en) Model animal in which state of disease condition is observable in real time, gene construct for achieving the same and use of the same
US5604131A (en) cDNA-genomic DNA hybrid sequence encoding APP770 containing a genomic DNA insert of the KI and OX-2 regions
US20130133090A1 (en) Transgenic mammalls modified in bri protein expression
CA2523888A1 (fr) Rat transgenique en tant que modele animal pour la choree de huntington humaine et constructions nucleaires, vecteurs et cellules pour leurs productions
JP5046413B2 (ja) ヒトｆａｄプレセニリン突然変異をもつ標的遺伝子組換え非ヒト哺乳動物および生殖による子孫
EP1116790A1 (fr) Modele murin caracterise par la mutation conditionelle du gene smn - utilisation pour l'etude de l'atrophie musculaire spinale et d'autres maladies neurodégénératives et myopathies musculaires
Buck et al. Experimental models of tau aggregation
US7445904B2 (en) Cysteine string protein and its role in neurodegenerative diseases
Wadsworth et al. Transgenic mouse expressing APP 770
Wang The functions of FE65 proteins and their roles in dementias of the Alzheimer type
Cho et al. Ha HY, Cho IH, Lee KW, Lee KW, Song JY, Kim KS et al.. The axon guidance defect of the telencephalic commissures of the JSAP1-deficient brain was partially rescued by the transgeni...
WO2007085706A1 (fr) Procédé de criblage de substances pour le traitement de maladies neuropsychiatriques et matériels pour ce procédé

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990712

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): CH DE FR GB LI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010703